Patent Update: Angiotensin-II Antagonists: Patent Activity since the Discovery of DuP-753
- 1 October 1992
- journal article
- Published by Informa Healthcare in Current Opinion on Therapeutic Patents
- Vol. 2 (10) , 1693-1718
- https://doi.org/10.1517/13543776.2.10.1693
Abstract
(1992). Patent Update: Angiotensin-II Antagonists: Patent Activity since the Discovery of DuP-753. Current Opinion on Therapeutic Patents: Vol. 2, No. 10, pp. 1693-1718. doi: 10.1517/13543776.2.10.1693Keywords
This publication has 18 references indexed in Scilit:
- The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclaseBiochemical and Biophysical Research Communications, 1992
- Chapter 7. Angiotensin / Renin ModulatorsPublished by Elsevier ,1991
- Preliminary biochemical characterization of two angiotensin II receptor subtypesBiochemical and Biophysical Research Communications, 1989
- Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitorsBMJ, 1988
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme.BMJ, 1987
- Effect of enalapril on the skin response to bradykinin in man.British Journal of Clinical Pharmacology, 1987
- EnalaprilDrugs, 1986
- Purification and characterization of human converting enzyme (kininase II)Peptides, 1981
- Use of an Angiotensin II Antagonist (Saralasin) in the Recognition of “Angiotensinogenic” HypertensionNew England Journal of Medicine, 1975